Issue Date: March 20, 2006
Novo signs two drug pacts
Novo Nordisk has licensed antibody technology from Durham, N.C.-based Argos Therapeutics for the development of drugs to treat systemic immune disorders. The deal could be worth up to $69 million for Argos, which will receive up-front and milestone payments, as well as royalties on any drugs developed through its technology. Using its dendritic cell-based technology platform, Argos has found monoclonal antibodies that target INF-alpha, which is vital to the onset and maintenance of lupus. Separately, Novo has signed an agreement to study the use of Nastech Pharmaceutical's molecular biology-based drug delivery technology with several of its compounds.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society